The role of individualized antiplatelet therapy after PCI
█ Review
DOI: 10.26430/CHUNGARICA.2022.52.5.373
Authors:
Aradi Dániel1,2, Óvári Péter1, Nagy-Kardos Cintia1, Tihanyi László1, Veress Gábor1
1Állami Szívkórház, Balatonfüred
2Semmelweis Egyetem, Városmajori Szív- és Érgyógyászati Klinika, Budapest
Summary
After percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is required for a certain period of time to effectively prevent thrombotic complications after stent implantation. Currently, the length of DAPT and the type of ADP P2Y12 inhibitor depend mostly on the indication: in case of acute coronary syndrome (ACS), DAPT featuring a potent P2Y12 inhibitor (prasugrel or ticagrelor) is recommended for one year, while in case of elective PCI, the recommended treatment is aspirin plus clopidogrel for six months. Since the bleeding and thrombotic risks of our patients differ significantly, it is easy to understand that this very simplified approach is inappropriate to achieve the best clinical outcomes; therefore, it might be preferable to use individualized DAPT protocols. The Authors aim to review the possibilities of individualizing dual antiplatelet therapies by defining the patients’ thrombotic and bleeding risks and summarize the currently available evidence on the clinical effectiveness of individualized antiplatelet therapy.
ISSUE: CARDIOLOGIA HUNGARICA | 2022 | VOLUME 52, ISSUE 5
click here to read the full article |
click here to read the pdf |
|
| watch CH Live interview |